Abstract: The disclosure relates to pharmaceutical combinations comprising an HDAC6 selective inhibitor and a CD20 inhibitory antibody for the treatment of a B-cell disorder, such as cancer, in a subject in need thereof. Also provided herein are methods for treating a B-cell disorder in a subject in need thereof, comprising administering to the subject an effective amount of an HDAC6 selective inhibitor and a CD20 inhibitory antibody.

Abstract: The invention relates to methods for using biomarkers to identify cancer patients that will or are likely to respond to treatment. Specifically, the invention relates to the use of one or more of three association studies of cancer types, gene mutations, or gene expression levels in order to identify cancer patients that will or are likely to respond to treatment with a histone deacetylase (HDAC) inhibitor, alone or in combination with another cancer treatment. The methods may, optionally, further include treating such patient with an HDAC inhibitor, alone or in combination with another cancer treatment.

Abstract: The disclosure relates to pharmaceutical combinations comprising an HDAC6 selective inhibitor and a CD20 inhibitory antibody for the treatment of a B-cell disorder, such as cancer, in a subject in need thereof. Also provided herein are methods for treating a B-cell disorder in a subject in need thereof, comprising administering to the subject an effective amount of an HDAC6 selective inhibitor and a CD20 inhibitory antibody.

Abstract: The invention relates to methods for using biomarkers to identify cancer patients that will or are likely to respond to treatment. Specifically, the invention relates to the use of one or more of three association studies of cancer types, gene mutations, or gene expression levels in order to identify cancer patients that will or are likely to respond to treatment with a histone deacetylase (HDAC) inhibitor, alone or in combination with another cancer treatment. The methods may, optionally, further include treating such patient with an HDAC inhibitor, alone or in combination with another cancer treatment.

Abstract: A hybrid approach for personalized recommendation of subject matter description is described, comprising: inputting the description into an analyzing engine, the analyzing engine performing the steps of: extracting at least one of metadata, ID and Title from the description; tokenizing the description to generate tokenized data; normalizing the tokenized data to produce Cast information; stemming the tokenized data to generate stemmed data; pattern matching the stemmed data to produce Genre information; word sense disambiguating the stemmed data to produce Feature information; tagging the word sense disambiguated data to produce Topic information; arriving a concise descriptor of the description.

Abstract: A requirements matching broker is provided for use in a requirements matching system. The broker receives messages from users or from other brokers, conveying a statement of requirements, via a communications network interface. The broker includes a store and means to store predetermined rules for routing received messages. A rule includes a statement of requirements and the identity of a corresponding destination. On receipt of a message, the broker performs a comparison of a statement of requirements conveyed by the message with a statement of requirements contained within a stored routing rule. On finding a match, the broker identifies, from the matching routing rule, the identity of a destination for routing the received message and transmits the message to the identified destination via the network interface.